search
Back to results

Effect of Weight Management Programs on Cardiometabolic Risk Profile in Overweight Women (FM-01)

Primary Purpose

Overweight and Obesity, Dyslipoproteinemia

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Meal replacement (MR)
Control (C)
Verum
Placebo
Sponsored by
Bonn Education Association for Dietetics r.A., Cologne, Germany
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Overweight and Obesity focused on measuring Weight Management Programs, Weight loss stabilization, Cardiometabolic risk

Eligibility Criteria

18 Years - 60 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • BMI: between 27.0 and 34.9 kg/m²
  • One of the following blood lipids: total cholesterol ≥ 200 mg/dL, LDL-cholesterol ≥ 175 mg/dL, HDL-cholesterol ≤ 50 mg/dL, TG 150-400 mg/dL
  • women, 18-60 years

Specific Exclusion Criteria:

  • lactose or protein intolerance
  • hypo- or hyperthyroidism
  • pharmacological treatment of diabetes
  • intake of vitamins or mineral supplements
  • anticoagulants
  • cardiac pacemaker
  • contraindications to exercise

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm Type

    Active Comparator

    Other

    Active Comparator

    Placebo Comparator

    Arm Label

    Meal replacement (MR) group

    Control (C) group

    Verum group

    Placebo group

    Arm Description

    Energy-restricted modified diet with MR for weight control dietary supplement: MR shakes, soups or bars. Duration: 3-month weight loss phase (phase 1) During weight stabilization phase (phase 2) MR counted to food choice option.

    Energy-restricted modified diet without MR for weight control. Duration: 3-month weight loss phase (phase 1) During 3-month weight stabilization phase (phase 2) MR counted to food choice option.

    Specific micronutrient composition with omega-3 fatty acids (capsules) Duration: 6-month weight maintenance phase (phase 3)

    Placebo capsules Duration: 6-month weight maintenance phase (phase 3)

    Outcomes

    Primary Outcome Measures

    Weight loss (phase 1)
    Intervention changes in body weight
    Total antioxidant capacity (phase 3)
    Intervention changes in total antioxidant capacity
    Fasting plasma cortisol concentration (phase 3)
    Intervention changes in fasting plasma cortisol concentration

    Secondary Outcome Measures

    Relative body fat (phase 1)
    Intervention changes in relative body fat
    Relative body weight (phase 1)
    Intervention changes in relative body weight
    Responder (weight loss > 5%) (phase 1)
    Responder rate after 12 weeks
    Waist circumference (phase 1)
    Intervention changes in waist circumference
    Total antioxidant capacity (phase 1)
    Intervention changes in total antioxidant capacity
    Fasting plasma cortisol concentration (phase 1)
    Intervention changes in fasting plasma cortisol concentration
    Relative body fat (phase 3)
    Intervention changes in relative body fat
    Relative body weight (phase 3)
    Intervention changes in relative body weight
    Responder (weight loss > 5%)
    Responder rate after 12 months
    Waist circumference (phase 3)
    Intervention changes in waist circumference

    Full Information

    First Posted
    March 29, 2017
    Last Updated
    April 6, 2017
    Sponsor
    Bonn Education Association for Dietetics r.A., Cologne, Germany
    Collaborators
    FomMed HealthCare AG
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03109834
    Brief Title
    Effect of Weight Management Programs on Cardiometabolic Risk Profile in Overweight Women
    Acronym
    FM-01
    Official Title
    Choice of Foods, Weight Loss and Metabolic Changes in Overweight Women Willing to Lose Weight With Dietary/Nutritional Therapy Intervention
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2017
    Overall Recruitment Status
    Completed
    Study Start Date
    March 25, 2004 (Actual)
    Primary Completion Date
    March 28, 2007 (Actual)
    Study Completion Date
    March 28, 2007 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Bonn Education Association for Dietetics r.A., Cologne, Germany
    Collaborators
    FomMed HealthCare AG

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Aim of this prospective randomized study was to evaluate whether a diet with meal replacements can be as effective as a conventional energy-restricted modified diet on weight loss, body composition and cardiometabolic risk profile in overweight women. Moreover, the impact of these two different weight management strategies was observed on cardiometabolic risk profile after a self-directed weight stabilization phase following the weight loss phase. After that, the effect of a specific micronutrient composition with omega-3 fatty acids versus placebo on cardiometabolic risk was observed during a following phase of weight loss maintenance.
    Detailed Description
    Abdominal obesity, atherogenic dyslipidemia and hypertension are essential risk factors for cardiovascular diseases. Several studies showed favorable effects of weight loss in overweight subjects on cardiometabolic risk profile. The study was divided into a 3-month weight loss phase (phase 1), a subsequent 3-month phase of weight stabilization (phase 2) and a 6-month phase of weight loss maintenance (phase 3). For a total of 6 months subjects were randomly assigned to the meal replacement (MR) or control (C) group at baseline I. During weight loss phase both dietary intervention groups followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1200 kcal/d. The MR-WL group (MR group during weight loss phase) was advised to replace two of three meals every day with meal replacements. The C-WL group (C group during weight loss phase) was advised to follow a conventional energy-restricted modified diet with 15-20% of energy intake in the form of protein, 50-55% of energy intake in the form of carbohydrates and 30% of energy intake in the form of fat. All participants attended ten group training sessions for nutrition education. During weight stabilization phase all women of MR-S and C-S group (MR and C group during weight stabilization phase) were encouraged to consume a self-directed well-balanced variety of nutrient-dense foods without meal intervention. However, the MR-S and C-S group were instructed to continue the implemented nutrition advice of weight loss phase. At the beginning of weight loss maintenance phase (baseline II) women were randomly assigned to the verum (specific micronutrient composition with omega-3 fatty acids) group or placebo group. Both groups were encouraged to consume a self-directed well-balanced variety of nutrient-dense foods. All women participated in an exercise program (fitness walking) on 1-2 days per week during all three phases of the study for a total of 12 months.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Overweight and Obesity, Dyslipoproteinemia
    Keywords
    Weight Management Programs, Weight loss stabilization, Cardiometabolic risk

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Model Description
    2 parallel arms in weight loss phase and weight stabilization phase (1. randomization at baseline I); 2 parallel arms in weight maintanance phase (2. randomization at baseline II)
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    105 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Meal replacement (MR) group
    Arm Type
    Active Comparator
    Arm Description
    Energy-restricted modified diet with MR for weight control dietary supplement: MR shakes, soups or bars. Duration: 3-month weight loss phase (phase 1) During weight stabilization phase (phase 2) MR counted to food choice option.
    Arm Title
    Control (C) group
    Arm Type
    Other
    Arm Description
    Energy-restricted modified diet without MR for weight control. Duration: 3-month weight loss phase (phase 1) During 3-month weight stabilization phase (phase 2) MR counted to food choice option.
    Arm Title
    Verum group
    Arm Type
    Active Comparator
    Arm Description
    Specific micronutrient composition with omega-3 fatty acids (capsules) Duration: 6-month weight maintenance phase (phase 3)
    Arm Title
    Placebo group
    Arm Type
    Placebo Comparator
    Arm Description
    Placebo capsules Duration: 6-month weight maintenance phase (phase 3)
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Meal replacement (MR)
    Intervention Description
    MR-WL group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1200 kcal/d and was advised to replace two meals, i.e. breakfast and dinner, every day with two MR shakes, soups or bars and to prepare their own lunch during 3-month weight loss phase (phase 1). During 3-month weight stabilization phase (phase 2) MR-S group (MR group during weight stabilization phase) were encouraged to consume a self-directed well-balanced variety of nutrient-dense foods without meal intervention. MR counted to food choice option. The MR-S group was instructed to continue the implemented nutrition advice of weight loss phase. Duration: 6 months (phase 1 and phase 2: baseline I - 6.month)
    Intervention Type
    Other
    Intervention Name(s)
    Control (C)
    Intervention Description
    During 3-month weight loss phase (phase 1) C-WL group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1200 kcal/d without MR for weight control. During 3-month weight stabilization (phase 2) phase C-S group (C group during weight stabilization phase) were encouraged to consume a self-directed well-balanced variety of nutrient-dense foods without meal intervention. MR counted to food choice option. The C-S group was instructed to continue the implemented nutrition advice of weight loss phase. Duration: 6 months (phase 1 and phase 2: baseline I - 6.month)
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Verum
    Intervention Description
    Verum: Specific micronutrient composition with omega-3 fatty acids (capsules) Verum group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1500 kcal/d and was advised to consume 3 verum-capsules twice a day (with breakfast and dinner) with 200 ml water during 6-month weight loss maintenance phase (phase 3). Duration: 6 months (6.month / baseline II - 12.month)
    Intervention Type
    Other
    Intervention Name(s)
    Placebo
    Intervention Description
    Placebo group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1500 kcal/d and was advised to consume 3 placebo-capsules twice a day (with breakfast and dinner) with 200 ml water during 6-month weight loss maintenance phase. Placebo contains no micronutrients and omega-3 fatty acids. Duration: 6 months (6.month / baseline II - 12.month)
    Primary Outcome Measure Information:
    Title
    Weight loss (phase 1)
    Description
    Intervention changes in body weight
    Time Frame
    3-month dietary intervention (from baseline I to 3rd month)
    Title
    Total antioxidant capacity (phase 3)
    Description
    Intervention changes in total antioxidant capacity
    Time Frame
    6-month dietary intervention (from baseline II to 12th month)
    Title
    Fasting plasma cortisol concentration (phase 3)
    Description
    Intervention changes in fasting plasma cortisol concentration
    Time Frame
    6-month dietary intervention (from baseline II to 12th month)
    Secondary Outcome Measure Information:
    Title
    Relative body fat (phase 1)
    Description
    Intervention changes in relative body fat
    Time Frame
    3-month dietary intervention (from baseline I to 3rd month)
    Title
    Relative body weight (phase 1)
    Description
    Intervention changes in relative body weight
    Time Frame
    3-month dietary intervention (from baseline I to 3rd month)
    Title
    Responder (weight loss > 5%) (phase 1)
    Description
    Responder rate after 12 weeks
    Time Frame
    3-month dietary intervention (from baseline I to 3rd month)
    Title
    Waist circumference (phase 1)
    Description
    Intervention changes in waist circumference
    Time Frame
    3-month dietary intervention (from baseline I to 3rd month)
    Title
    Total antioxidant capacity (phase 1)
    Description
    Intervention changes in total antioxidant capacity
    Time Frame
    3-month dietary intervention (from baseline I to 3rd month)
    Title
    Fasting plasma cortisol concentration (phase 1)
    Description
    Intervention changes in fasting plasma cortisol concentration
    Time Frame
    3-month dietary intervention (from baseline I to 3rd month)
    Title
    Relative body fat (phase 3)
    Description
    Intervention changes in relative body fat
    Time Frame
    6-month dietary intervention (from baseline II to 12th month)
    Title
    Relative body weight (phase 3)
    Description
    Intervention changes in relative body weight
    Time Frame
    6-month dietary intervention (from baseline II to 12th month)
    Title
    Responder (weight loss > 5%)
    Description
    Responder rate after 12 months
    Time Frame
    12 months (from baseline I to 12th month)
    Title
    Waist circumference (phase 3)
    Description
    Intervention changes in waist circumference
    Time Frame
    6-month dietary intervention (from baseline II to 12th month)

    10. Eligibility

    Sex
    Female
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    60 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: BMI: between 27.0 and 34.9 kg/m² One of the following blood lipids: total cholesterol ≥ 200 mg/dL, LDL-cholesterol ≥ 175 mg/dL, HDL-cholesterol ≤ 50 mg/dL, TG 150-400 mg/dL women, 18-60 years Specific Exclusion Criteria: lactose or protein intolerance hypo- or hyperthyroidism pharmacological treatment of diabetes intake of vitamins or mineral supplements anticoagulants cardiac pacemaker contraindications to exercise
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Christine Metzner, Professor MD
    Organizational Affiliation
    Bonn Education Association for Dietetics r.A., Cologne, Germany
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    21939523
    Citation
    Metzner CE, Folberth-Vogele A, Bitterlich N, Lemperle M, Schafer S, Alteheld B, Stehle P, Siener R. Effect of a conventional energy-restricted modified diet with or without meal replacement on weight loss and cardiometabolic risk profile in overweight women. Nutr Metab (Lond). 2011 Sep 22;8(1):64. doi: 10.1186/1743-7075-8-64.
    Results Reference
    result

    Learn more about this trial

    Effect of Weight Management Programs on Cardiometabolic Risk Profile in Overweight Women

    We'll reach out to this number within 24 hrs